drugset / Trial / NCT02035748
Assessment of Patients Treated With JETREA® for Vitreomacular Traction
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to observe the anatomical and functional outcomes of ocriplasmin (JETREA®) over a 6-month follow-up period.
Timeline
- Start
- 2014-04
- Primary completion
- 2015-09
- Completion
- 2015-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ocriplasmin | Protein / enzyme biologic | 0.125 mg | Intravitreal |
Indications
No indication recorded.